With unrestricted educational grant from
|
|
|
- Jasmine Phelps
- 9 years ago
- Views:
Transcription
1 HOTEL MAKSOUD PLAZA SÃO PAULO SP BRASIL OCTOBER 22-23, 2009
2 Organization With unrestricted educational grant from
3 As the President of the Brazilian Society of Internal Medicine and the Brazilian Clinical Research Institute (BCRI) I am honored to welcome you to the 2 nd. International Symposium of Thrombosis and Anticoagulation ISTA The main purpose of this symposium is to discuss the most recent evidence on thrombosis and anticoagulation, including new agents under development and novel diagnostic tools in the field. The focus is to understand how to better apply the evidence into clinical practice so that the patients will gain and you will enhance the quality of care you offer your patients. This meeting provides a unique opportunity to witness the latest knowledge in this field. The clinical aspects including the most update treatments are our major objective in order to offer you concise answers that will help in the patient management on a day-by-day basis. I Hope you enjoy this scientific program and take advantage of the presence of our expert national and international faculty. Antonio Carlos Lopes, MD, PhD, FACP Brazilian Society of Internal Medicine President
4
5 Co-Chairs Becker, Richard C. MD Lopes, Renato D. MD, MHS, PhD Federal University of Sao Paulo (UNIFESP-EPM) International Faculty Alexander, John H. Garcia, David University of New Mexico (USA) Granger, Christopher B. Handller, Allison Jolicoeur, E. Marc Montreal Heart Institute (Canada) Newby, L. Kristin Pieper, Karen S. National Faculty Baruzzi, Antonio Claudio Carvalho, Antonio Carlos Chamone, Dalton de Alencar F. Guimarães, Hélio Penna Lopes, Antonio Carlos Machado, Fabio Santana Timerman, Ari
6 Scientific Program OCTOBER 22, :00 09:10 Opening Antonio Carlos Lopes, Richard C. Becker, and Renato D. Lopes SESSION I President: Christopher B. Granger 09:10 09:30 Update in Thrombosis and Anticoagulation in Clinical Practice Richard C. Becker 09:40 10:00 Biomarkers of Thrombosis - How and Which one to Use? L. Kristin Newby 10:10 10:30 Anticoagulation in Acute Coronary Syndromes Ari Timerman 10:30 10:50 Coffee Break 10:50 11:10 Triple Therapy - A Management Dilemma Renato D. Lopes 11:20 11:40 Stroke: Should We use Antithrombotics? When and How? Fabio Santana Machado 11:40 12:00 Challenging Cases David Garcia 12:00 14:00 Break SESSION II President: E. Marc Jolicoeur 14:00 15:20 Thrombosis in: Diabetes: L. Kristin Newby Atrial Fibrillation: John H. Alexander Dyslipidemia: Christopher B. Granger Heart Failure/Hypertension: Antonio Carlos Carvalho 15:30 15:50 Management of Bleeding Episodes in Patients receiving Antithrombotic Therapy David Garcia 16:00 16:30 Coffee Break 16:30 17:00 Design Issues and Statistical Considerations around Clinical Research Karen Pieper 17:10 17:40 Challenging Cases Renato D. Lopes / E. Marc Jolicoeur
7 OCTOBER 23, 2009 SESSION III President: Antonio Carlos Lopes 09:00 09:20 VTE prophilaxis in Medical Patients Renato D. Lopes 09:25 09:55 Treatment for VTE Dalton de Alencar F. Chamone 10:00 10:20 Post-thrombotic Syndrome: Epidemiology and Management Richard C. Becker 10:20 10:40 Coffee Break 10:40 11:10 Predicting Cancer Patients at Risk for Venous Thromboembolism: Strategies for Prophylaxis David Garcia 11:15 11:45 Diagnosis and Management of Pulmonary Embolism Antonio Claudio Baruzzi 11:50 12:10 How to Better Interpret the Medical Literature? Karen Pieper 12:15 12:45 Challenging Cases L. Kristin Newby 12:45 14:00 Break SESSION IV President: Christopher B. Granger 14:00 14:20 Globalization of Clinical Research John H. Alexander 14:30 15:00 Anticoagulation in Special Patient Populations E. Marc Jolicoeur 15:10 15:30 Anticoagulation in Intensive Care Units Hélio Penna Guimarães 15:40 16:00 Coffee Break 16:00 16:20 The Latest ACCP Antithrombotic Therapy Guidelines: Important Changes that may Impact Clinical Practice David Garcia 16:30 16:50 Importance of Academic Coordinating Center in Clinical Trials in Thrombosis Allison Handller 17:00 17:30 Challenging Cases Renato D. Lopes / E. Marc Jolicoeur
8 SBCM President and Co-Chairs Antonio Carlos Lopes, MD, PhD, FACP 4 Full Professor of Internal Medicine, Federal University of São Paulo - Paulista School of Medicine 4 Full Professor of Emergency Medicine, Federal University of São Paulo - Paulista School of Medicine 4 PhD - Cardiology, Federal University of São Paulo Paulista School of Medicine 4 President of the Brazilian Society of Internal Medicine 4 President of the Brazilian Clinical Research Institute (BCRI) 4 Fellow of the American College of Physicians Richard C. Becker, MD 4 Professor of Medicine. Divisions of Cardiology and Hematology, Department of Medicine - Duke University Medical Center 4 Director of the Duke Cardiovascular Thrombosis Center Duke Clinical Research Institute (DCRI) 4 Co-director of the Advanced Biomarkers Program Duke Clinical Research Institute (DCRI) Renato Delascio Lopes MD, MHS, PhD 4 Adjunct Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Assistant Director - Clinical Research Fellowship Program Duke Clinical Research Institute (DCRI) 4 Assistant Professor - Department of Internal Medicine Federal University of Sao Paulo - Paulista School of Medicine 4 Executive Director - Brazilian Clinical Research Institute (BCRI)
9 Invited Speakers Christopher B. Granger, MD, FACC 4 Professor of Medicine - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Director, Cardiac Care Unit - Duke University Medical Center 4 Co-Director of Cardiovascular Clinical Trials Duke Clinical Research Institute L. Kristin Newby, MD, MHS 4 Associate Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Co-director of the Cardiac Care Unit Duke University Hospital 4 Co-director of the Advanced Biomarkers Program Duke Clinical Research Institute (DCRI) John Alexander, MD, MHS, FACC 4 Associate Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Director of Early Phase Cardiovascular Research Duke Clinical Research Institute (DCRI) 4 Medical director of Site-Based Clinical Research in Cardiovascular Medicine Duke University Medical Center David Garcia, MD 4 Associate Professor - Department of Internal Medicine Division of Hematology/Oncology University of New Mexico Health Sciences Center 4 Director of Cancer and Thrombosis at the University of New Mexico Cancer Center - Director of the Anticoagulation Management Service at University Hospital
10 Invited Speakers E. Marc Jolicœur, MD, MSc, FRCP 4 Assistant Professor - Division of Cardiology, Department of Medicine - University of Montreal 4 Research Associate, University of Montreal Karen S. Pieper, MS 4 Associate Director for Faculty and Fellow Affairs and Clinical Trials Statistical Operations. Duke Clinical Research Institute (DCRI) Allison Handller RN, BSN, MS 4 Senior Project Leader Cardiovascular Devices Phase III/IV Cardiovascular Mega trials Duke Clinical Rsearch Institute (DCRI) Antonio Carlos Carvalho, MD, PhD, FACC 4 Full Professor of Cardiology, Federal University of São Paulo - Paulista School of Medicine 4 PhD - Cardiology, Federal University of São Paulo - Paulista School of Medicine 4 Scientific Director of the Brazilian Clinical Research Institute (BCRI) 4 Fellow of the American College of Cardiology Dalton de Alencar Fischer Chamone, MD, PhD 4 Full Professor of Hematology and Hemotherapy, São Paulo University Medical School 4 PhD - Hematology and Hemottherapy, University of Louvain, Belgium 4 Associate Professor, São Paulo University Pharmaceutical Sciences School
11 Ari Timerman, MD, PhD 4 Assistant Professor of Cardiology, ABC Foundation School of Medicine, 4 PhD - Cardiology, São Paulo University Medical School 4 Head of the Emergency and Intensive Therapy Division, Dante Pazzanese Institute of Cardiology 4 President of the Cardiopulmonary Resuscitation Division of the Dante Pazzanese Institute of Cardiology 4 Head Professor of the TIC5007, Cardiovascular Emergencies of the Postgraduate Program USP/IDPC Medicine/Technology and Intervention in Cardiology Antonio Claudio Baruzzi, MD, PhD 4 PhD - Cardiology, Institute of the Heart, São Paulo University Medical School 4 Physician of the Intensive Care Center, Albert Einstein Hospital Fabio Santana Machado, MD 4 Medical Coordinator of the Neurosurgical ICU of the Neurosurgery, São Paulo University Medical School 4 Collaborator Professor of the Internal Medicine, São Paulo University Medical School 4 Physician of the Neuro-Intensive Care Unit, Sírio Libanês Hospital Hélio Penna Guimarães, MD 4 Assistant Professor of Internal Medicine, Federal University of São Paulo - Paulista School of Medicine 4 President of the Chapter of Emergency Medicine of the Brazilian Society of Internal Medicine 4 Medical Coordinator, Teaching, Training and Simulation Center, Heart Hospital 4 Financial Director of the Brazilian Clinical Research Institute (BCRI)
12 Organization Support With unrestricted educational grant from Symposium Secretariat Caixa Postal: CEP: São Paulo SP Fax: [email protected]
Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment
How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto
News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval
New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
Thrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
Investor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
Center of Excellence in Naturopathic Cardiovascular Medicine
Introducing the Center of Excellence in Naturopathic Cardiovascular Medicine The Heart & Lung Wellness program at Center for Natural Medicine and National College of Natural Medicine WHO WE ARE A Center
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
From Concept to a Published Paper - a guide to excellence in Medical Research.
The Course Directors of the New Frontiers in Interventional Cardiology (NFIC), Krakow Cardiovascular Research Institute (KCRI) and Proper Medical Writing (PMW) would like to welcome you to the seminar:
June 2014 CURRICULUM VITAE. Peter E. Friedell, M. D. FACP. 2850 S. Wabash Suite 203. Chicago, Illinois
CURRICULUM VITAE June 2014 Peter E. Friedell, M. D. FACP. 2850 S. Wabash Suite 203 Chicago, Illinois 60616 312-808-0621 office 312-505-5106 cell 815-328-3833 fax [email protected] Personal: Date of Birth
Prior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
Committee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
21st Annual OSF Cardiovascular Symposium
21st Annual OSF Cardiovascular Symposium new waves in cardiac electrophysiology saturday 18 october 2014 7:00 a.m. 4:00 p.m. embassy suites conference center east peoria, illinois OBJECTIVES Overall Program:
Bringing Science to Clinical Practice: BEST OF ACC 2015
MAY 29 30, 2015 Eden Roc Miami Beach Bringing Science to Clinical Practice: BEST OF ACC 2015 COURSE DIRECTORS Robert O. Bonow, MD, MACC G. William Dec Jr., MD, FACC COURSE CO-DIRECTORS Akshay S. Desai,
2014 Emerging Faculty Participants
Nazem Akoum, MD, FACC Assistant Professor of Medicine, Clinical Cardiac Electrophysiology EPIC EMR Cardiology Liaison University of Utah Health Sciences [email protected] Areas of Interest: Cardiac
Minimally Invasive Cardiac Surgery
3rd Annual Bakken Symposium Minimally Invasive Cardiac Surgery December 7 & 8, 2009 Mayo Auditorium, COURSE DIRECTORS: Kenneth K. Liao, MD, PhD James D. St. Louis, MD Presented by Department of Surgery
7th annual ConFerenCe location
Sponsors 7th Annual WOMEN and Ischemic Heart Disease Symposium Friday, April 19, 2013 Offered in cooperation with the California Chapter of the American College of Cardiology and WomenHeart: The National
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014. Participating Faculty
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014 Participating Faculty Hector O. Ventura, MD, FACC Section Head, Cardiomyopathy and
CHAPTER. 9th Annual Meeting October 12, 2013 8:00 am - 4:30 pm University of Kentucky Albert B. Chandler Hospital Auditorium Lexington, Kentucky
Kentucky CHAPTER 9th Annual Meeting October 12, 2013 8:00 am - 4:30 pm Albert B. Chandler Hospital Auditorium Lexington, Kentucky Coronary Pathologies: Atherosclerosis and Beyond Please join your fellow
Gruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
Brooklyn Stroke Symposium 2015
Brooklyn Stroke Symposium 2015 May 28, 2015 Brooklyn Public Library Grand Army Plaza Sponsored by Keynote Presentations Sleep Apnea and Stroke: More than a Snore Devin L. Brown, M.D., M.S. Professor of
Duke Regional Diabetes Symposium 2012
Duke Regional Diabetes Symposium 2012 July 13, 2012 8:30 AM 4:30 PM North Carolina Research Campus David H. Murdock Core Laboratory Building First Floor Event Room 150 Research Campus Drive Kannapolis,
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
2012 Innovations in Heart Failure and Pulmonary Hypertension
ALLEGHENY GENERAL HOSPITAL CARDIOVASCULAR INSTITUTE PRESENTS 2012 Innovations in Heart Failure and Pulmonary Hypertension Friday, September 28, 2012 Marriott Pittsburgh City Center Pittsburgh, Pennsylvania
EXHIBITOR PROSPECTUS
American Stroke Association 4 th Annual Connecticut Stroke Conference: TRUMBULL MARRIOTT MERRITT PARKWAY, TRUMBULL, CT EXHIBITOR PROSPECTUS To Whom It May Concern: On behalf of the American Stroke Association,
Cardiac Care Associates 2014 Annual Meeting
Cardiac Care Associates 2014 Annual Meeting March 7, 2014 Villa Christina Restaurant at Perimeter Co-provided by the American College of Cardiology Foundation and The Georgia Chapter of the American College
CARDIOLOGY UPDATE 2004
Division of Cardiology Department of Medicine University of California, San Francisco School of Medicine CARDIOLOGY UPDATE 2004 September 30 - October 2, 2004 Carmel Valley Ranch Carmel, California University
23 rd Annual Conference on Cardiovascular Nursing
23 rd Annual Conference on Cardiovascular Nursing Thursday, April 11, 2013 7:00 am - 3:45 pm Boston Marriott Newton Newton, MA Keynote Speaker Marvin A. Konstam, MD Chief Physician Executive, The CardioVascular
EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012
EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial
ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Eliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
Anticoagulation at the end of life. Rhona Maclean [email protected]
Anticoagulation at the end of life Rhona Maclean [email protected] Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
INTERPRETING CLINICAL DATA: Highlights From ASCO 2016
INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 SATURDAY, JUNE 25, 2016 Detroit Marriott - Troy, MI AGENDA Time Topic Speaker 7:30 am Registration and Continental Breakfast 8:00 am Opening Remarks/Welcome
INTRODUCTION. For supporting information, we invite you to explore. Our Corporate Website. and its Media Center
INTRODUCTION PRESENT e-learning Systems is both a pioneer in the combining of online social networking with CME medical education, and using these web properties and opt-in members lists to deliver effective
HHT Center of Excellence The University of Texas, Southwestern. Dallas, Texas
HHTCenterofExcellence TheUniversityofTexas,Southwestern Dallas,Texas Medical Director, Pulmonary Consultant Daniel Goodenberger, M.D. Professor of Medicine Phone (214)857-0409 FAX (214)857-1457 e-mail:
Cardiac Rehabilitation: Strategies Approaching 2020
ACC Banff 2015 Cardiac Rehabilitation: Strategies Approaching 2020 James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Libin Cardiovascular
A C C O M M O D A T I O N S D I R E C T I O N S. Exhibitor tables will be accessible at 7:30 a.m.
R E g I S T R AT I O N I N F O R M AT I O N There is a $55 fee for Christiana Care Health System (CCHS) employees ($75 day of registration, if seating permits), $75 fee for non-cchs employees ($95 day
Stroke/VTE Quality Measure Build for Meaningful Use Stage 1
Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Presented by Susan Haviland, BSN RN Senior Consult, Santa Rosa Consulting Meaningful Use Quality Measures Centers for Medicare and Medicaid Services
Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital
Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Jonathan Sykes MD, CMIO Jacalyn Liebowitz RN, MBA,NEA-BCFACHE VP Care Continuum Allegiance Health - Jackson, MI DISCLAIMER:
AnMed Health Disparities Dashboard
AnMed Health Quick Facts 588 Bed Acute Care System Level II Trauma Center Emergency Department visits: 112,329 Admissions: 23,489 Active Medical Staff: 455 Employees: 3,511 Source : CY2013 Setting the
FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M.
CEDARS-SINAI HYPERTENSION CENTER 2016 Clinical Highlights Symposium FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M. CONFERENCE LOCATION Harvey Morse Conference Center 8701 Gracie Allen Drive Plaza Level,
2016 Cardiovascular Update
2016 Cardiovascular Update March 18, 2016 Villa Christina Restaurant at Perimeter Jointly Provided by the American College of Cardiology Foundation and The Georgia Chapter of the American College of Cardiology
Heart Failure: From Prevention to Intervention
Sharp HealthCare Presents Heart Failure: From Prevention to Intervention Saturday, May 16, 2015 DoubleTree by Hilton Hotel San Diego - Mission Valley San Diego, Calif. As medical professionals, we know
Establishing a Course of Excellence. Duvall, WA 98019 Or Complete This Form and Return. PH: 425.844.9019 to Gaffney Events
Office Phone: Mobile Phone: TYPE OF PRACTICE Please Specify REGISTRATION FEES: PRIOR TO 6/1/16 $150 DPM / Physician $50 Student $75 Nurse / PA / Technician / Resident $150 Industry Representative REGISTRATION
Backgrounder. Current anticoagulant therapies
Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events
EXHIBITOR PROSPECTUS
American Heart Association Newton Marriott, Newton, MA EXHIBITOR PROSPECTUS To Whom It May Concern: On behalf of the American Heart Association and the members of the Boston Cardiovascular Nursing committee,
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
May 20, 2016. May 21, 2016. The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium. Comprehensive Stroke Symposium
The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium May 20, 2016 Comprehensive Stroke Symposium May 21, 2016 Emergency Neurological Life Support Course and Certification The Richmond Marriott
CURRICULUM VITAE. NAME: Stephen Harold Arnold Hernandez, PhD, RN
CURRICULUM VITAE NAME: Stephen Harold Arnold Hernandez, PhD, RN CONTACT INFORMATION: Address UNM College of Nursing MSC09 5350 1 University of New Mexico Albuquerque, New Mexico 87131-0001 Office Phone
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
24 th Annual Conference on Cardiovascular Nursing
24 th Annual Conference on Cardiovascular Nursing Presented by the American Heart Association s Boston Cardiovascular Nursing Committee Wednesday, April 2, 2014 7:00 am - 3:45 pm Boston Marriott Newton,
Curriculum Vitae. 2100 Statonsburg Road (252)847-5875
Curriculum Vitae 2100 Statonsburg Road (252)847-5875 Greenville, NC 27834 [email protected] Education/Training PGY2 Specialty Practice Residency, Cardiology July 2009-June 2010 Columbus, OH PGY1
FACULTY OF ALLIED HEALTH SCIENCES
FACULTY OF ALLIED HEALTH SCIENCES 102 Naresuan University FACULTY OF ALLIED HEALTH SCIENCES has focused on providing strong professional programs, including Medical established as one of the leading institutes
3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism NATHAN T. CONNELL, MD, MPH; JAMES N. BUTERA, MD ABSTRACT Until recently, warfarin has been
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
Updates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
AMERICAN COLLEGE of CARDIOLOGY
AMERICAN COLLEGE of CARDIOLOGY CARDIAC CARE ASSOCIATE MEMBERSHIP APPLICATION Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant Clinical Pharmacist Improve Patient Care,
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
Coronary CTA in the Emergency Department A Hands-on Workshop
Coronary CTA in the Emergency Department A Hands-on Workshop November 7-8, 2009 Eden Roc Hotel Miami Beach, Florida Symposium Director Coronary CTA in the Emergency Department: A Hands-on Workshop Target
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary
About Medicine Specialists of Florida Hospital:
Welcome to Medicine Specialists of Florida Hospital. We look forward to serving you and your family in any way we can. Our physicians and staff strive to offer personalized care to each patient while maintaining
24 th Annual Frontiers in Critical Care Nursing. Presented by UMass Memorial Medical Center Heart and Vascular Center of Excellence
24 th Annual Frontiers in Critical Care Nursing Tuesday May 7, 2013 Presented by Heart and Vascular Center of Excellence $80 Early Registration by March 22 Best Western Royal Plaza Hotel 181 Boston Post
Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
San Antonio Heart Failure Symposium 2015
San Antonio Heart Failure Symposium 2015 Continuing Medical Education Saturday, February 28, 2015 Expert Faculty, 8 Hours CME, 8 Hours CEU Comprehensive review and latest updates in: - Heart failure -
xaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant. Cardiac Care Associate Membership application
American College of Cardiology Cardiac Care Associate Membership application Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant Improve Patient Care, Increase Facility Performance,
UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
Service Specification Template Department of Health, updated June 2015
Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st
PHYSICIANS SAMIA KHOURY, MD PROFESSOR, DIRECTOR, ABU-HAIDAR NEUROSCIENCE INSTITUTE AND MULTIPLE SCLEROSIS CENTER
1 PHYSICIANS SAMIA KHOURY, MD PROFESSOR, DIRECTOR, ABU-HAIDAR NEUROSCIENCE INSTITUTE AND MULTIPLE SCLEROSIS CENTER Dr. Samia Khoury is the Jack, Sadie, and David Breakstone Professor of Neurology at Harvard
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
Anticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
Tennessee Chapter Scientific Meeting
Tennessee Chapter Scientific Meeting 2016 October 28 29, 2016 Franklin Marriott Cool Springs Franklin, Tennessee Register Online Today! www.cvent.com/d/qfqbcy/4w Keeping App With the Guidelines: Evidence-Based
STEMI & CARDIAC ARREST
STEMI & CARDIAC ARREST CONFERENCE 2015 May 6, 2015 Registration 7:30 am Program 7:50 am 4:00 pm East Carolina Heart Institute at East Carolina University Greenville, NC Jointly Provided by East Carolina
Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
Sanford Health/UNDSMHS Cerebrovascular Symposium
Discover. Inspire. Grow. Sanford Health/UNDSMHS Cerebrovascular Symposium January 23, 2016 Ramada Plaza & Suites 1635 42nd Street South Fargo, North Dakota (701) 277-9000 This symposium is supported in
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
